[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100450614":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":20,"locations":25,"responsibleParty":44,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":20,"maxAge":20,"enrollmentInfo":54,"targetDuration":20,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":28,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"The Foundation for Orthopaedics and Regenerative Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group (AlloRx)","EXPERIMENTAL","intravenous and intracavernosal or interstitial delivery (total dose of 100 million cells)",[13],"Biological: AlloRx",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","AlloRx","cultured allogeneic adult umbilical cord derived mesenchymal stem cells",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Chadwick Prodromos, MD","PRINCIPAL_INVESTIGATOR",[26],{"facility":27,"status":28,"city":29,"state":20,"zip":20,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Medical Surgical Associates Center","RECRUITING","St John's","Antigua and Barbuda","AG",{"type":33,"coordinates":34},"Point",[35,36],-61.84329,17.12096,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":42,"phoneExt":20,"email":43},"Chadwick Prodromos, M.D.","CONTACT","8476996810","care@thepsci.com",{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100450614","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-stem-cells-for-peyronies-disease-ed-and-interstitial-cystitis-100450614",false,"NCT05147779","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis","Inclusion Criteria:\n\n* Diagnosis of Peyronie's Disease, erectile dysfunction, or Interstitial Cystitis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur","ALL",{"count":55,"type":56},20,"ESTIMATED","INTERVENTIONAL",[59],"PHASE1","This trial will study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis",[62,63,64],"Erectile Dysfunction","Peyronie's Disease","Interstitial Cystitis",[62,63,66,64],"stem cell treatment","2025-04-15",{"date":69,"type":70},"2025-04-17","ACTUAL",{"date":72,"type":70},"2021-09-12",{"date":74,"type":56},"2025-12",{"name":5,"class":6},1]